MedTrace Logo

Dose Escalation TTHX1114 Ophthalmic Solution

NCT05769920 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 8

Last updated 2023-04-18

No results posted yet for this study

Summary

Dose escalation 3+3 design with accelerated titration 4 dose levels

Conditions

  • Corneal Epithelial Degeneration

Interventions

DRUG

TTHX1114(NM141) Ophthalmic Solution

Eye drop twice daily

Sponsors & Collaborators

  • Trefoil Therapeutics, Inc.

    lead INDUSTRY

Principal Investigators

  • Thomas Tremblay · Trefoil Therapeutics.com

Study Design

Allocation
NON_RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-12-06
Primary Completion
2023-04-12
Completion
2023-04-12
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05769920 on ClinicalTrials.gov